ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

betamethasone dipropionate

Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.

Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.

Drug pageBetamethasone dipropionate: every studyMany companies study it; this page follows only the 26 they lead. All 42 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 3, 200526 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharmaits history only180 open or runningphase 4since Nov 3, 2005Sep 15, 2005none ahead
MC2 Therapeuticsits history only50 open or runningphase 3since Oct 9, 2017Oct 9, 2017none ahead
Glenmark Pharmaceuticals Ltd. Indiaits history only10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
Huadong Medicineits history only10 open or runningphase 3since Dec 11, 2025Dec 11, 2025none ahead
Primus Pharmaceuticals10 open or runningphase 4since Apr 13, 2016Apr 13, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Primus Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 13, 2016First study: phase 4 study in Plaque PsoriasisFirst studyNCT02749799 · 45 enrolled · United States

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Primus Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02749799Plaque Psoriasis · United States4CompletedJul 201645

How it is read

Names in the registry

  • “LEO 90100”, 7 entries
  • “MC2-01 cream”, 4 entries
  • “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
  • “MC2-01 Cream”, 2 entries
  • “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.